Rei Suzuki

Dr. Rei Suzuki

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2016 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
RSRei Suzuki
Rei Suzuki
TTTadayuki Takagi
Tadayuki Takagi
THTakuto Hikichi
Takuto Hikichi
NKNaoki Konno
Naoki Konno
MSMitsuru Sugimoto
Mitsuru Sugimoto
HOHiromasa Ohira
Hiromasa Ohira
As gemcitabine is a key anti-tumor agent for unresectable pancreatic ductal adenocarcinoma (PDAC), it is important to predict the outcomes of gemcitabine chemotherapy. The present study aimed to confirm whether the derived neutrophil‑to‑lymphocyte ratio (dNLR) is able to predict chemotherapy outcomes. To elucidate the role of dNLR in patients that underwent chemotherapy, the current study evaluated clinicopathological variables in 31 patients with unresectable PDAC treated with gemcitabine. The correlation between clinicopathological variables, and progression‑free survival (PFS) and overall survival (OS) time were investigated. Univariate analysis revealed that there were no significant differences in PFS and OS as a function of age (<65 vs. ≥65 years), gender, tumor location (pancreas head vs. body/tail), tumor diameter (<23 vs. ≥23 mm) or serum carbohydrate antigen 19‑9 concentration level (<3,800 vs. ≥3,800 U/ml). However, disease stage (locally advanced vs. metastatic) and the dNLR (<2.5 vs. ≥2.5) significantly affected PFS and OS. Multivariate analysis subsequently revealed that a dNLR of ≥2.5 was an independent prognostic factor for poor PFS (P=0.003) and OS (P=0.026). In conclusion, data from the present study suggests that the pre‑treatment dNLR is an independent prognostic factor to predict PFS and OS in patients with unresectable PDAC treated with gemcitabine. This indicates that dNLR has a potential role in stratifying patients that may benefit from gemcitabine therapy.

23 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
THTakuto Hikichi
Takuto Hikichi
JNJun Nakamura
Jun Nakamura
MTMika Takasumi
Mika Takasumi
MHMinami Hashimoto
Minami Hashimoto
Tsunetaka KatoTsunetaka Kato
Tsunetaka Kato
HOHiromasa Ohira
Hiromasa Ohira
Endoscopic resection has been the standard treatment for intramucosal esophageal cancers (ECs) because of the low risk of lymph node metastases in the lesions. In recent years, endoscopic submucosal dissection (ESD), which can resect large ECs, has been performed. However, the risk of esophageal stricture after ESD is high when the mucosal defect caused by the treatment exceeds 3/4 of the circumference of the lumen. Despite the subsequent high risk of luminal stricture, ESD has been performed even in cases of circumferential EC. In such cases, it is necessary to take measures to prevent stricture. Therefore, in this review, we aimed to clarify the current status of stricture prevention methods after esophageal ESD based on previous literature. Although various prophylactic methods have been reported to have stricture-preventing effects, steroid injection therapy and oral steroid administration are mainstream. However, in cases of circumferential EC, both steroid injection therapy and oral steroid administration cannot effectively prevent luminal stricture. To solve this issue, clinical applications, such as tissue shielding methods with polyglycolic acid sheet, autologous oral mucosal epithelial sheet transplantation, and stent placement, have been developed. However, effective prophylaxis of post-ESD mucosal defects of the esophagus is still unclear. Therefore, further studies in this research field are needed.

1 January 2019 in Pancreatology
Verified
Journal Article
Closed access
HAHiroyuki Asama
Hiroyuki Asama
RSRei Suzuki
Rei Suzuki
THTakuto Hikichi
Takuto Hikichi
TTTadayuki Takagi
Tadayuki Takagi
AMAtsushi Masamune
Atsushi Masamune
HOHiromasa Ohira
Hiromasa Ohira

26 February 2022 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
RSRei Suzuki
Rei Suzuki
YOYoshinori Okubo
Yoshinori Okubo
TTTadayuki Takagi
Tadayuki Takagi
MSMitsuru Sugimoto
Mitsuru Sugimoto
YSYuki Sato
Yuki Sato
HOHiromasa Ohira
Hiromasa Ohira
Background: We aimed to clarify the role of complement C3a and its receptor C3aR in progression of pancreatic ductal adenocarcinoma (PDAC). Materials and Methods: We evaluated the serum levels of C3 and C3a in patients with PDAC. C3aR expression in tissue was assessed using a tissue microarray. To confirm the protumoral effects of C3a in PDAC, we conducted in vitro experiments using PDAC cell lines (Panc-1 and MiaPaca-2) that exhibit high C3aR expression. Results: Serum levels of both C3 and C3a were higher in 26 patients with PDAC than in 28 nontumor-bearing controls. In the tissue microarray, we observed increased expression of C3aR in PDAC cells, especially in cases with metastatic lesions. In vitro experiments showed that C3a facilitated tumor cell proliferation, migration and invasion by activating the extracellular-regulated kinase signaling pathway and inducing epithelial-to-mesenchymal transition. Inhibition of the C3a-C3aR axis by pharmacological blockade and short-hairpin RNA-mediated knockdown of C3aR alleviated its protumoral effect. Conclusion: These findings provide a new approach for the development of treatments targeting the C3a–C3aR axis.

10 August 2018 in Molecular and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HAHiroyuki Asama
Hiroyuki Asama
RSRei Suzuki
Rei Suzuki
TTTadayuki Takagi
Tadayuki Takagi
MSMitsuru Sugimoto
Mitsuru Sugimoto
NKNaoki Konno
Naoki Konno
HOHiromasa Ohira
Hiromasa Ohira
Predicting the prognosis of unresectable pancreatic ductal adenocarcinoma (PDAC) is useful in determining the appropriate management strategy. The present study aimed to investigate the association between PDAC prognosis and inflammation‑based markers, such as the neutrophil‑to‑lymphocyte ratio (NLR), platelet‑to‑lymphocyte ratio, prognostic nutritional index, modified Glasgow prognostic score (mGPS) and controlling nutritional status score. A total of 72 patients with unresectable PDAC who received chemotherapy were included. Inflammation‑based markers were measured prior to treatment. The median progression‑free survival (PFS) and overall survival (OS) were 117 days (range, 10‑781 days) and 244 days (range 43‑781 days), respectively. The cut‑off value of continuous variables that predicted the median OS (244 days) was calcualted. Univariate analysis of PFS showed that disease stage, first‑line chemotherapy regimen, carcinoembryonic antigen (CEA), NLR, platelet‑to‑lymphocyte ratio (PLR), mGPS and controlling nutritional status (CONUT) scores were associated with PFS. Among them, stage, first‑line chemotherapy regimen, CEA, NLR and mGPS were independent prognostic factors for PFS in multivariate analysis. Univariate analysis of OS showed that stage, first‑line chemotherapy regimen, CA19‑9, NLR, PLR, prognostic nutritional index (PNI), mGPS and CONUT score were associated wtih OS. Among them, first‑line chemotherapy and mGPS were independent prognostic factors for OS according to multivariate analysis. Univariate and multivariate analyses revealed that a NLR ≥4.0 and mGPS 2 were independent prognostic factors for PFS. For OS, mGPS 2 was an independent prognostic factor. In conclusion, mGPS was the most useful marker in predicting the prognosis of patients with unresectable PDAC who received chemotherapy.

24 February 2013 in Diagnostic and Therapeutic Endoscopy
Verified
Journal Article
Open access
PDF file
RSRei Suzuki
Rei Suzuki
Atsushi IrisawaAtsushi Irisawa
Atsushi Irisawa
MBManoop S. Bhutani
Manoop S. Bhutani
Since the development of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in the early 1990s, its application has been extended to various diseases. For pancreatic cancer, EUS-FNA can obtain specimens from the tumor itself with fewer complications than other methods. Interventional EUS enables various therapeutic options: local ablation, brachytherapy, placement of fiducial markers for radiotherapy, and direct injection of antitumor agents into cancer. This paper will focus on EUS-guided oncologic therapy for pancreatic cancer.